iBio Inc (IBIO)

1.77 -0.13 (-6.84%) USD  |  NYAM  |  Apr 25, 13:28
More

iBio Research and Development Expense (Quarterly): 1.535M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2007. Upgrade now.
Date Value
December 31, 2023 1.535M
September 30, 2023 1.606M
June 30, 2023 2.356M
March 31, 2023 2.644M
December 31, 2022 2.779M
September 30, 2022 2.548M
June 30, 2022 3.562M
March 31, 2022 3.272M
December 31, 2021 1.859M
September 30, 2021 1.134M
June 30, 2021 3.097M
March 31, 2021 2.162M
December 31, 2020 2.374M
September 30, 2020 1.862M
June 30, 2020 0.583M
March 31, 2020 1.095M
December 31, 2019 0.888M
September 30, 2019 0.977M
June 30, 2019 1.624M
March 31, 2019 1.453M
December 31, 2018 1.273M
September 30, 2018 1.124M
June 30, 2018 1.042M
March 31, 2018 0.966M
December 31, 2017 0.993M
Date Value
September 30, 2017 0.985M
June 30, 2017 1.112M
March 31, 2017 1.136M
December 31, 2016 1.049M
September 30, 2016 0.82M
June 30, 2016 0.853M
March 31, 2016 1.048M
December 31, 2015 0.704M
September 30, 2015 0.551M
June 30, 2015 0.764M
March 31, 2015 0.815M
December 31, 2014 0.731M
September 30, 2014 1.185M
June 30, 2014 -0.589M
March 31, 2014 0.343M
December 31, 2013 0.585M
September 30, 2013 -0.489M
June 30, 2013 0.967M
March 31, 2013 0.631M
December 31, 2012 0.656M
September 30, 2012 1.177M
June 30, 2012 1.055M
March 31, 2012 1.307M
December 31, 2011 1.162M
September 30, 2011 1.457M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

0.583M
Minimum
Jun 2020
3.562M
Maximum
Jun 2022
1.998M
Average
1.862M
Median
Sep 2020

Research and Development Expense (Quarterly) Benchmarks

Lixte Biotechnology Holdings Inc 0.1491M
PAVmed Inc 3.595M
Avalo Therapeutics Inc 1.867M
Imunon Inc 3.553M
Ocugen Inc 9.504M